Jan Johansson
Works at
Sources: reporter.nih.gov
Grants and prizes
R44, Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PK, R44AG099463, 2026–2028, 17 Sept 2026
UG3, CS6253 Sequential Subcutaneous Pharmacokinetic Study followed by Phase 2A Placebo-Controlled Trial with Three Fixed Doses in APOE4 MCI and AD Patients to assess Safety, PK, and Biomarker Effects, UG3AG098023, 2026–2028, 3 Mar 2026
Sources: reporter.nih.gov